Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Epilepsy × Sirolimus × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 7 Multiple Myeloma 6 Graft vs Host Disease 5 Myelodysplastic Syndromes 4 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Gliosarcoma 3 Glioblastoma 3 Brain Neoplasms 3 Waldenstrom Macroglobulinemia 2 Tuberous Sclerosis 2 Prostatic Neoplasms 2 Neurofibrosarcoma 2 Myeloproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Lung Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Hodgkin Disease 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2 Triple Negative Breast Neoplasms 1 Tongue Neoplasms 1

Interventions

Temozolomide 1 Sulfasalazine 1 Sirolimus 1 Radiotherapy 1 Memantine 1 Gabapentin 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04595513 2024-05-16

STOP2

Children's Hospital Medical Center, Cincinnati

Phase 1/2 Completed

5 enrolled 15 charts

Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡